Myriad Genetics

Abbott, Boston Scientific Stents & Stuff (at CNBC)

yahoo.com     01-Jul-2008   1 related          

So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling...                    

comments

Health Winners & Losers: Halozyme (at TheStreet.com)

yahoo.com     01-Jul-2008   12 related          

Health stocks traded Tuesday on a variety of business and regulatory news. The Nasdaq and Amex biotechnology indices hopped 1.7% and 1.4%, respectively. They outdid the Amex pharmaceutical index, which registered a 0.8% rise,...                    

comments

                   
go.com: Alzheimers go.com

Myriad Genetics Stops Work on an Alzheimer's Drug

pharmiweb.co.uk     01-Jul-2008   51 related          

New York Times - Jul. 01, 2008 A drug under development by Myriad Genetics to treat Alzheimer's disease failed in a closely watched late-stage clinical trial, dealing another blow to efforts to combat the illness. Myriad said...                    

comments

Myriad, Lundbeck Alzheimer's drug fails key study

pharmiweb.co.uk     30-Jun-2008   5 related          

Reuters Health - Jun. 30, 2008 By Gelu Sulugiuc COPENHAGEN (Reuters) - Flurizan, an experimental drug for Alzheimer's disease, failed to help patients in a pivotal clinical test, dealing a blow to its backers Myriad Genetics...                    

comments

                   

Biotech Could Go After Pharmaceutical Companies As it Gears Up for Mass Market Diseases

pharmiweb.co.uk     01-Jul-2008   2 related          

Leave it to conventional wisdom and pharmaceutical companies would continue to buy biotech companies as they search for much needed growth. “Pharmaceutical companies are becoming like biotech companies and biotech companies are...                    

comments

Genentech (DNA) NewsBite - DNA Rises as Competing Drug Fails

pharmiweb.co.uk     01-Jul-2008          

Posted on Monday, June 30, 2008 10:58 AM Genentech (DNA) opened at $73.53. So far today the stock has hit a low of $73.53 and a high of $74.81. DNA is now trading at $74.78, up 2.06 (2.83%). After hitting a one-year low of...                    

comments

Elan (ELN) NewsBite - Elan Rises on Competitors' Failed Drug Study

pharmiweb.co.uk     01-Jul-2008          

Posted on Monday, June 30, 2008 10:20 AM Elan Corp. (ELN) opened at 35.27. So far today, the stock has hit a low of 35.27 and a high of 35.85. ELN is now trading at 35.33, up 0.42 (1.19%). The stock hit its 52 week high of...                    

comments

                   

Movers: H&R Block, France Telecom, Mesa Air, Del Monte

businessweek.com     30-Jun-2008   60 related          

H&R Block posts $2.11, vs. $1.81 a year ago, fourth quarter EPS from continuing operations on 11% revenue rise. It sees fiscal year 2009 EPS from continuing operations of $1.60-$1.70. Also says it now expects adjusted fiscal...                    

comments

                   

Movers: NDS Group, H&R Block, France Telecom, Mesa Air, Del Monte

businessweek.com     30-Jun-2008   4 related          

NDS Group PLC confirms that it has received a takeover proposal from News Corp. and two newly incorporated companies formed by funds advised by Permira Advisers for $60 per share per ADS. H&R Block posts $2.11, vs. $1.81 a year...                    

comments

                   
451press.com: Brains need drugs 451press.com

Alzheimer's Drug Fails Clinical Trail

451press.com     01-Jul-2008   12 related          

People with migraines and chronic headaches go through a lot of worries, one of whih si that they will get Alzheimer's. We're not alone in this worry. A recent study from the MetLife foundation showed that more Americans are...                    

comments